Posts by John

Viking Therapeutics has launched a Phase 1 trial for VK3019. Explore the safety, objectives, and clinical implications of this new drug development initiative.

New South African research is revolutionizing global tuberculosis treatment, introducing shorter, safer regimens to replace outdated clinical standards.

The FDA has rejected the NDA for cytisinicline due to manufacturing issues. Clinical safety and efficacy data remain strong; approval awaits process updates.

Are you paying for your CRO’s AI platform updates? Discover why mid-study software changes are causing friction and how to protect your clinical trial budget.

Mabwell secures NMPA approval for a novel LILRB4/CD3 bispecific T-cell engager, marking a breakthrough in the treatment of aggressive blood cancers.

Explore the hidden privacy risks in medical AI, from data re-identification to deep learning vulnerabilities, and how to protect patient data security.

Discover how the drug atrasentan is revolutionizing IgA nephropathy treatment by reducing proteinuria and protecting long-term kidney function.

Discover five essential facts about daraxonrasib, a breakthrough KRAS inhibitor offering new hope for treating aggressive pancreatic cancer.

Explore new anthropometric research on facial index variations among medical students and its significance for clinical anatomy and forensic medicine.

HHS is proposing strict new clinical trial reforms to protect U.S. biotech innovation and stop the Chinese sector from accessing sensitive medical data.